Talaris Therapeutics, Inc.
NASDAQ:TALS
2.72 (USD) • At close October 19, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 0.267 | 4.088 | 13.415 | 14.641 | 14.981 | 13.187 | 14.196 | 10.59 | 9.183 | 7.57 | 6.468 | 4.382 | 3.956 | 3.402 | 3.535 |
| General & Administrative Expenses
| 9.114 | 6.026 | 6.182 | 5.184 | 4.842 | 5.228 | 4.218 | 3.798 | 3.874 | 3.487 | 2.537 | 2.453 | 2.182 | 1.335 | 1.439 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 9.114 | 6.026 | 6.182 | 5.184 | 4.842 | 5.228 | 4.218 | 3.798 | 3.874 | 3.487 | 2.537 | 2.453 | 2.182 | 1.335 | 1.439 |
| Other Expenses
| 0.089 | 6.388 | 4.481 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 9.47 | 10.114 | 19.597 | 19.825 | 19.823 | 18.415 | 18.414 | 14.388 | 13.057 | 11.057 | 9.005 | 6.835 | 6.138 | 4.737 | 4.974 |
| Operating Income
| -8.932 | -16.502 | -24.078 | -19.825 | -19.823 | -18.415 | -18.414 | -14.388 | -13.057 | -11.057 | -9.005 | -6.835 | -6.138 | -4.737 | -4.974 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.917 | -6.388 | 1.581 | 1.297 | 0.812 | 0.319 | 0.155 | 0.147 | 0.116 | -0.295 | -0.294 | 0.056 | -0.279 | 0.074 | 0.126 |
| Income Before Tax
| -7.015 | -14.738 | -22.497 | -18.528 | -19.011 | -18.096 | -18.259 | -14.241 | -12.941 | -11.352 | -9.299 | -6.779 | -6.417 | -4.663 | -4.848 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 4.624 | -1.581 | -3.542 | -0.812 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -7.015 | -14.738 | -20.916 | -14.986 | -18.199 | -18.096 | -18.259 | -14.241 | -12.941 | -11.352 | -9.299 | -6.779 | -6.417 | -4.663 | -4.848 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.64 | -3.49 | -5 | -3.61 | -4.4 | -0.44 | -0.45 | -0.35 | -0.32 | -0.41 | -0.23 | -0.32 | -0.3 | -0.22 | -0.23 |
| EPS Diluted
| -1.64 | -3.49 | -5 | -3.61 | -4.4 | -0.44 | -0.45 | -0.35 | -0.32 | -0.41 | -0.23 | -0.32 | -0.3 | -0.22 | -0.23 |
| EBITDA
| -8.932 | -3.465 | -14.477 | -19.272 | -19.253 | -17.864 | -17.926 | -14.2 | -12.89 | -10.924 | -8.87 | -6.71 | -6.009 | -4.636 | -4.882 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |